Servier India is facilitating access to IVOSIDENIB through Servier India’s Managed Access Program (MAP) for:
• Adult IDH1 mutated Acute Myeloid Leukemia (AML) – as a partial paid program
(available in 1+2 bundle – 1 month paid and subsequent 2 months free of charge)
• Adult Locally Advanced or Metastatic mIDH1 Cholangiocarcinoma - as a partial paid program (available in 1+2 bundle – 1 month paid and subsequent 2 months free of charge)
• Pediatric IDH1 mutated patients (across indications) – as a compassionate access program (free of cost)
If you have a patient who may benefit from IVOSIDENIB, you may either reach out to us to at med.info-india@servier.com or any of the following to initiate the request / for more information (including pricing)
• 1st Point of Contact:
Dr Dipanjan Bhattacharjee – Medical Lead (Oncology) and Responsible Person for Medical Information (RPMI)
Mob. No. - +91-9167851461
Email ID – dipanjan.bhattacharjee@servier.com
OR
Dr Upal Vyas – Medical Lead ( Oncology)
Mob No.- +919619595111
Email ID - upal.vyas@servier.com
• 2nd Point of contact:
Dr Pranav Sopory – Country Medical Director
Mob. No. - +91- 9999491690
Email ID - pranav.sopory@servier.com
Please note that this communication is for informational purposes only and is not intended to advertise or promote the product. As an international pharmaceutical company governed by a Foundation, Servier is committed to therapeutic progress to serve patients’ needs. Ensuring equitable and sustainable access to our treatments across countries where we operate is our priority. Use of IVOSIDENIB should be based solely on your independent clinical judgment and the needs of your patient.
SERVIER INDIA PRIVATE LIMITED 1703,
17th Floor, Parinee Crescenzo, B Wing, G Block,
C 38 & 39, Behind MCA, Bandra Kurla Complex,
Bandra East, Mumbai 400051 - INDIA.
Contact us at:
